PHILADELPHIA--(BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells ...

Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading biotechnology company specializing in tools and technologies for the development of induced pluripotent stem cell (iPSC)-based ...

HAMBURG, GERMANY / ACCESSWIRE / December 19, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has received a US$ 2.5 m ...

This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential ...

Induced pluripotent stem cell technology is a promising, rapidly evolving field with the potential to transform cell-based therapeutics across a range of disease areas that have significant unmet ...

Aspen's ISCT presentations will cover automated manufacturing of autologous iPSC-derived neuron replacement therapies The presentations at ISCT focus on Aspen's development of automated production of ...

SAN DIEGO--(BUSINESS WIRE)--Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement ...

iXCells’ cell engineering platform iPSCore ™ is a unified and dedicated system where tools, skills, experiences and expertise are structured together to design, develop and build iPSC-derived cell ...